Replies to post #221946 on Biotech Values

[DewDiligence]

NVS did actually claim “cost-effectiveness” at a price of $4-5M, but (to reiterate) I would not make too much of this assertion:

https://uk.reuters.com/article/novartis-gene-therapy/novartis-says-sma-gene-therapy-is-cost-effective-at-4-5-mln-per-patient-idUKFWN1XG0OD